Marechal F, Berthiot G, Cattan A
Department of Medical Oncology, Institut Jean Godinot, Reims, France.
Acta Oncol. 1990;29(8):989-94. doi: 10.3109/02841869009091788.
Cisplatin (CDDP) and etoposide are synergistic in vitro: the aim of this study was to evaluate the efficacy of a continuous infusion (C.I.) of these 2 drugs in inoperable non-small cell lung cancer. Patients were to receive 3 courses of CDDP 20 mg/m2/d in 1 l saline x 5d and etoposide 50 mg/m2/d in 21 saline x 5d--both in C.I.--every 3-4 weeks. Thirty patients have entered the study. Four were inevaluable for response. One patient got complete remission, 15 partial remission, 8 no change and 2 progressive disease. The response rate was 53.3% overall (95% confidence interval: 35-71%), and 61.5% for 26 assessable patients. Toxicity appeared to be acceptable despite 52% transient neutropenia--one patient died during aplasia--and 78% grade 1 to 3 nausea or vomiting. Treatment was stopped in only one case, and modified in 6 others. The high response rate that we observed, supports the idea of potentiation of the antineoplastic effect of CDDP and etoposide by C.I., in non-small cell lung cancer. These results must be confirmed in larger series before definitive conclusions can be drawn.
顺铂（CDDP）和依托泊苷在体外具有协同作用：本研究的目的是评估持续输注这两种药物对无法手术的非小细胞肺癌的疗效。患者每3 - 4周接受3个疗程的治疗，顺铂20 mg/m²/d加入1升生理盐水中持续输注5天，依托泊苷50 mg/m²/d加入2升生理盐水中持续输注5天。30例患者进入研究。4例因无法评估疗效被排除。1例患者完全缓解，15例部分缓解，8例病情无变化，2例病情进展。总体缓解率为53.3%（95%置信区间：35 - 71%），26例可评估患者的缓解率为61.5%。尽管有52%的患者出现短暂性中性粒细胞减少（1例患者在再生障碍期间死亡）以及78%的患者出现1 - 3级恶心或呕吐，但毒性似乎是可接受的。仅1例患者停止治疗，6例患者调整了治疗方案。我们观察到的高缓解率支持了持续输注可增强顺铂和依托泊苷对非小细胞肺癌抗肿瘤作用的观点。在得出明确结论之前，这些结果必须在更大规模的研究中得到证实。
